Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CS2009 |
| Synonyms | |
| Therapy Description |
CS2009 is a trispecific antibody that targets PDCD1 (PD-1), CTLA4, and VEGFA, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CS2009 | CS-2009|CS 2009|J30 | CTLA4 Antibody 33 PD-L1/PD-1 antibody 132 VEGFA Antibody 5 | CS2009 is a trispecific antibody that targets PDCD1 (PD-1), CTLA4, and VEGFA, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06741644 | Phase Ib/II | Paclitaxel Oxaliplatin Etoposide Capecitabine CS2009 Carboplatin Pemetrexed Disodium Nab-paclitaxel | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Recruiting | AUS | 1 |